Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
International Stem Cell Corp. stock logo
ISCO
International Stem Cell
$0.19
+4.4%
$0.13
$0.05
$0.20
$1.44M-0.146,255 shs4,250 shs
Novus Therapeutics, Inc. stock logo
NVUS
Novus Therapeutics
$3.40
-0.6%
$13.23
$4.50
$27.32
$4.88M2.0778,851 shs555,122 shs
BetterLife Pharma Inc. stock logo
PVOTF
BetterLife Pharma
$0.00
$0.03
$0.38
$21.70MN/A52,703 shs198,200 shs
Tonix Pharmaceuticals Holding Corp. stock logo
TNXP
Tonix Pharmaceuticals
$42.36
+10.4%
$32.16
$6.76
$130.00
$282.22M2.05963,389 shs1.03 million shs
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
International Stem Cell Corp. stock logo
ISCO
International Stem Cell
+4.44%+47.68%+56.54%+69.37%+65.78%
Novus Therapeutics, Inc. stock logo
NVUS
Novus Therapeutics
-0.58%+11.11%+13.71%+20.14%+39.92%
BetterLife Pharma Inc. stock logo
PVOTF
BetterLife Pharma
0.00%0.00%0.00%0.00%0.00%
Tonix Pharmaceuticals Holding Corp. stock logo
TNXP
Tonix Pharmaceuticals
+10.43%+19.32%+12.24%+150.95%-31.68%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
International Stem Cell Corp. stock logo
ISCO
International Stem Cell
1.0475 of 5 stars
0.05.00.00.01.91.70.0
Novus Therapeutics, Inc. stock logo
NVUS
Novus Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
BetterLife Pharma Inc. stock logo
PVOTF
BetterLife Pharma
N/AN/AN/AN/AN/AN/AN/AN/A
Tonix Pharmaceuticals Holding Corp. stock logo
TNXP
Tonix Pharmaceuticals
2.6485 of 5 stars
3.52.00.00.01.03.30.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
International Stem Cell Corp. stock logo
ISCO
International Stem Cell
0.00
N/AN/AN/A
Novus Therapeutics, Inc. stock logo
NVUS
Novus Therapeutics
0.00
N/AN/AN/A
BetterLife Pharma Inc. stock logo
PVOTF
BetterLife Pharma
0.00
N/AN/AN/A
Tonix Pharmaceuticals Holding Corp. stock logo
TNXP
Tonix Pharmaceuticals
3.00
Buy$585.001,281.02% Upside

Current Analyst Ratings Breakdown

Latest TNXP, NVUS, PVOTF, and ISCO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/3/2025
Tonix Pharmaceuticals Holding Corp. stock logo
TNXP
Tonix Pharmaceuticals
Alliance Global Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
(Data available from 7/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
International Stem Cell Corp. stock logo
ISCO
International Stem Cell
$9.09M0.17N/AN/A($0.49) per share-0.38
Novus Therapeutics, Inc. stock logo
NVUS
Novus Therapeutics
N/AN/AN/AN/A$13.13 per shareN/A
BetterLife Pharma Inc. stock logo
PVOTF
BetterLife Pharma
N/AN/AN/AN/A$0.01 per shareN/A
Tonix Pharmaceuticals Holding Corp. stock logo
TNXP
Tonix Pharmaceuticals
$10.09M30.90N/AN/A$31.82 per share1.33
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
International Stem Cell Corp. stock logo
ISCO
International Stem Cell
-$210K-$0.04N/AN/A-3.39%N/A-5.71%8/11/2025 (Estimated)
Novus Therapeutics, Inc. stock logo
NVUS
Novus Therapeutics
-$16.01M-$21.58N/AN/AN/AN/A-133.49%-30.52%N/A
BetterLife Pharma Inc. stock logo
PVOTF
BetterLife Pharma
-$14.78MN/AN/AN/AN/AN/A-205.15%-147.23%N/A
Tonix Pharmaceuticals Holding Corp. stock logo
TNXP
Tonix Pharmaceuticals
-$130.04M-$1,963.61N/AN/AN/A-1,313.87%-120.96%-101.28%8/15/2025 (Estimated)

Latest TNXP, NVUS, PVOTF, and ISCO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/14/2025Q1 2025
International Stem Cell Corp. stock logo
ISCO
International Stem Cell
N/A-$0.03N/A-$0.03N/A$2.13 million
5/12/2025Q1 2025
Tonix Pharmaceuticals Holding Corp. stock logo
TNXP
Tonix Pharmaceuticals
-$3.23-$2.84+$0.39-$2.84$2.55 million$2.43 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
International Stem Cell Corp. stock logo
ISCO
International Stem Cell
N/AN/AN/AN/AN/A
Novus Therapeutics, Inc. stock logo
NVUS
Novus Therapeutics
N/AN/AN/AN/AN/A
BetterLife Pharma Inc. stock logo
PVOTF
BetterLife Pharma
N/AN/AN/AN/AN/A
Tonix Pharmaceuticals Holding Corp. stock logo
TNXP
Tonix Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
International Stem Cell Corp. stock logo
ISCO
International Stem Cell
N/A
0.75
0.51
Novus Therapeutics, Inc. stock logo
NVUS
Novus Therapeutics
N/A
18.78
18.78
BetterLife Pharma Inc. stock logo
PVOTF
BetterLife Pharma
N/A
3.62
3.62
Tonix Pharmaceuticals Holding Corp. stock logo
TNXP
Tonix Pharmaceuticals
N/A
12.31
11.64

Institutional Ownership

CompanyInstitutional Ownership
International Stem Cell Corp. stock logo
ISCO
International Stem Cell
N/A
Novus Therapeutics, Inc. stock logo
NVUS
Novus Therapeutics
N/A
BetterLife Pharma Inc. stock logo
PVOTF
BetterLife Pharma
N/A
Tonix Pharmaceuticals Holding Corp. stock logo
TNXP
Tonix Pharmaceuticals
82.26%
CompanyEmployeesShares OutstandingFree FloatOptionable
International Stem Cell Corp. stock logo
ISCO
International Stem Cell
308.00 million1.48 millionNot Optionable
Novus Therapeutics, Inc. stock logo
NVUS
Novus Therapeutics
71.44 millionN/ANot Optionable
BetterLife Pharma Inc. stock logo
PVOTF
BetterLife Pharma
N/A171.41 millionN/ANot Optionable
Tonix Pharmaceuticals Holding Corp. stock logo
TNXP
Tonix Pharmaceuticals
507.36 million7.36 millionNot Optionable

Recent News About These Companies

Tonix Pharma Unveils Promising TNX-801 Vaccine Findings
Tonix Pharma Publishes Phase 3 Trial Results

New MarketBeat Followers Over Time

Media Sentiment Over Time

International Stem Cell stock logo

International Stem Cell OTCMKTS:ISCO

$0.19 +0.01 (+4.44%)
As of 07/10/2025 03:21 PM Eastern

International Stem Cell Corporation, a clinical stage biotechnology company, focuses on the development of therapeutic and biomedical products in the United States, Asia, Europe, and internationally. It develops ISC- hpNSC, a neural stem cell program that has completed the Phase I clinical trial for the treatment of Parkinson's disease, as well as for treating stroke and traumatic brain injury. The company also offers anti-aging skin care products, including ProPlus Advanced Defense Complex, ProPlus Advanced Recovery Complex, ProPlus Eye Firming Complex, ProPlus Neck Firming Complex, ProPlus Advanced Aqueous Treatment, ProPlus Collagen Booster, ProPlus Elastin Booster, and ProPlus Brightening Toner. In addition, it provides human cell culture products comprising human skin cells and reagents for the study of skin disease, toxicology, or wound healing; human cells from the heart and blood vessels, and reagents to study cardiovascular disease and cancer; human bronchial and tracheal cell lines for the study of toxicity, cystic fibrosis, asthma, and pathogenesis; and human mammary epithelial cell lines for the study of breast cancer, three dimensional culture, and carcinogen screening. Its human cell culture products also comprise adult stem cells and reagents for regenerative medicine; human prostate cells and specialized medium to study prostate disease; human renal and bladder cells and media to study renal and bladder diseases; human corneal cells and media for the study of corneal disease; human female reproductive system cells for the study of cellular physiology; human skeletal muscle cells for the study of biology, diabetes, insulin receptor studies, muscle metabolism, muscle tissue repair, and myotube development; and other cell culture reagents and supplements for the growth, staining, and freezing of human cells. International Stem Cell Corporation was founded in 2001 and is headquartered in San Diego, California.

Novus Therapeutics stock logo

Novus Therapeutics NASDAQ:NVUS

Novus Therapeutics, Inc., a specialty pharmaceutical company, focuses on developing products for patients with disorders of ear, nose, and throat. Its lead product is OP0201, a surfactant-based nasal aerosol drug-device combination product for patients at risk for, or with, otitis media (OM) (middle ear inflammation with or without infection). The company also has a foam-based drug delivery technology OP0101 and OP0102 that could be used to deliver drugs into the ear, nose, and sinus cavities. Novus Therapeutics, Inc. is headquartered in Irvine, California.

BetterLife Pharma stock logo

BetterLife Pharma OTCMKTS:PVOTF

BetterLife Pharma, Inc. is an early stage pharmaceutical company, which engages in the development and commercialization of therapeutic pharmaceutical and nutraceutical products. It also offers drug delivery platform technologies. Its product lines include capsules, tablets, and softgels; bulk powder; stick packs; beverages; oral solutions; lotions, creams, and gels; pet food additives; gum, mints, and candies; and sexual health products. It distributes its product under the Pivot Naturals brand. The company was founded on June 10, 2002 and is headquartered in Vancouver, Canada.

Tonix Pharmaceuticals stock logo

Tonix Pharmaceuticals NASDAQ:TNXP

$42.36 +4.00 (+10.43%)
Closing price 07/10/2025 04:00 PM Eastern
Extended Trading
$42.39 +0.03 (+0.07%)
As of 04:09 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults. Its portfolio focuses on central nervous system disorders, as well as rare disease, immunology, and infectious disease product candidates. The company's priority is to submit a New Drug Application (NDA) to the FDA for TNX-102 SL (cyclobenzaprine HCl sublingual tablet), which has completed two positive Phase 3 studies for the management of fibromyalgia. TNX-102 SL is also being developed to treat fibromyalgia-type Long COVID, a chronic post-acute COVID-19 condition. Its TNX-1300 (cocaine esterase) is a biologic designed to treat cocaine intoxication and has been granted breakthrough therapy designation by the FDA. The company's rare disease development portfolio comprises TNX-2900, an intranasal potentiated oxytocin for the treatment of Prader-Willi syndrome (PWS). Its immunology portfolio includes TNX-1500, which is a biologic to address organ transplant rejection and autoimmune diseases. The company's infectious disease pipeline includes TNX-801, a vaccine in development to prevent smallpox and mpox. TNX-801 also serves as the live virus vaccine platform or recombinant pox vaccine platform for other infectious diseases, including TNX-1800 and TNX-1850, in development as a vaccine to protect against COVID-19. Its infectious disease development portfolio also comprises TNX-3900, and TNX-4200 are orally available CD45 antagonists in preclinical development. Tonix Pharmaceuticals Holding Corp. has collaboration agreement with Bilthoven Biologicals to advance TNX-801 mpox vaccine candidate; and with X-Chem, Inc. to develop broad-spectrum antivirals. The company was founded in 2007 and is headquartered in Chatham, New Jersey.